The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Development trends for human monoclonal antibody therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,423
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Ziegler, E. J., Fisher, C. J., Sprung, C. L., Straube, R. C., Sadoff, J. C., Foulke, G. E., Wortel, C. H., Fink, M. P., Dellinger, R. P., Teng, N. N. H., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102143240701 · Cited by 1,611
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Making antibody fragments using phage display libraries
Clackson, T., Hoogenboom, H. R., Griffiths, A. D., & Winter, G. (1991) · Nature · doi:10.1038/352624a0 · Cited by 1,203
Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., & Johnson, K. S. (1996) · Nature Biotechnology · doi:10.1038/nbt0396-309 · Cited by 1,027
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
Harding, F. A., Stickler, M. M., Razo, J., & DuBridge, R. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 737
Monoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C. J., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 733
Self-citationImmunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609
Wallace, D. J., Stohl, W., Furie, R. A., Lisse, J. R., McKay, J. D., Merrill, J. T., Petri, M. A., Ginzler, E. M., Chatham, W. W., McCune, W. J., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24699 · Cited by 585
Bartelds, G. M., Wijbrandts, C. A., Nurmohamed, M. T., Stapel, S., Lems, W. F., Aarden, L., Dijkmans, B. A. C., Tak, P. P., & Wolbink, G. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.065615 · Cited by 562
Immunogenicity of protein therapeutics
De Groot, A. S., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 545
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
McCloskey, R. V., Straube, R. C., Sanders, C., Smith, S. M., Smith, C. R., & and CHESS Trial Study Group. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-1-199407010-00001 · Cited by 495
Human antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Antigen-specific human antibodies from mice comprising four distinct genetic modifications
Lonberg, N., Taylor, L. D., Harding, F. A., Trounstine, M., Higgins, K. M., Schramm, S. R., Kuo, C.-C., Mashayekh, R., Wymore, K., McCabe, J. G., et al. (1994) · Nature · doi:10.1038/368856a0 · Cited by 398
Development trends for monoclonal antibody cancer therapeutics
Reichert, J. M., & Valge-Archer, V. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2241 · Cited by 389
Self-citationHuman-human hybridomas producing monoclonal antibodies of predefined antigenic specificity.
Olsson, L., & Kaplan, H. S. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.9.5429 · Cited by 379
Green, L. L., Hardy, M. C., Maynard-Currie, C. E., Tsuda, H., Louie, D. M., Mendez, M. J., Abderrahim, H., Noguchi, M., Smith, D. H., Zeng, Y., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-13 · Cited by 355
Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies.
Teng, N. N., Kaplan, H. S., Hebert, J. M., Moore, C., Douglas, H., Wunderlich, A., & Braude, A. I. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.6.1790 · Cited by 313
Current Status and Future Prospects
Wood, C., Baker, G., & Trounson, A. (1984) · Clinical In Vitro Fertilization · doi:10.1007/978-1-4471-3317-9_2 · Cited by 300
Dhimolea, E. (2010) · mAbs · doi:10.4161/mabs.2.1.10328 · Cited by 270
Self-citationMonoclonal Antibodies as Innovative Therapeutics
Reichert, J. (2008) · Current Pharmaceutical Biotechnology · doi:10.2174/138920108786786358 · Cited by 265
Self-citationShankar, G., Pendley, C., & Stein, K. E. (2007) · Nature Biotechnology · doi:10.1038/nbt1303 · Cited by 260
Human immunoglobulin allotypes: Possible implications for immunogenicity
Jefferis, R., & Lefranc, M.-P. (2009) · mAbs · doi:10.4161/mabs.1.4.9122 · Cited by 235
Green, L. L. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00137-4 · Cited by 229
Human monoclonal antibody production
James, K., & Bell, G. T. (1987) · Journal of Immunological Methods · doi:10.1016/0022-1759(87)90170-0 · Cited by 223
Comparing ELISA and Surface Plasmon Resonance for Assessing Clinical Immunogenicity of Panitumumab
Lofgren, J. A., Dhandapani, S., Pennucci, J. J., Abbott, C. M., Mytych, D. T., Kaliyaperumal, A., Swanson, S. J., & Mullenix, M. C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.7467 · Cited by 197
Minimizing the immunogenicity of protein therapeutics
Chirino, A. J., Ary, M. L., & Marshall, S. A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02953-2 · Cited by 177
Kozbor, D., & Roder, J. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.127.4.1275 · Cited by 156
Immunogenicity, efficacy and adverse events of adalimumab in RA patients
Bender, N. K., Heilig, C. E., Dröll, B., Wohlgemuth, J., Armbruster, F.-P., & Heilig, B. (2006) · Rheumatology International · doi:10.1007/s00296-006-0183-7 · Cited by 155
Lecluse, L. L. A., Driessen, R. J. B., Spuls, P. I., de Jong, E. M. G. J., Stapel, S. O., van Doorn, M. B. A., Bos, J. D., & Wolbink, G. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2009.347 · Cited by 148
Reichert, J. M. (2010) · mAbs · doi:10.4161/mabs.2.1.10677 · Cited by 93
Self-citationMazumdar, S. (2009) · mAbs · doi:10.4161/mabs.1.6.10195 · Cited by 90
Zhang, B. (2009) · mAbs · doi:10.4161/mabs.1.4.8895 · Cited by 79
Anti-infective monoclonal antibodies: perils and promise of development
Reichert, J. M., & Dewitz, M. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1987 · Cited by 58
Self-citationMining human antibody repertoires
Beerli, R. R., & Rader, C. M. (2010) · mAbs · doi:10.4161/mabs.12187 · Cited by 57
Pageau, S. C. (2009) · mAbs · doi:10.4161/mabs.1.3.8592 · Cited by 54
The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders
Emmi, L., & Chiarini, F. (2002) · Neurological Sciences · doi:10.1007/s100720200010 · Cited by 49
Nechansky, A. (2009) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2009.07.013 · Cited by 47
Olsson, L., Andreasen, R. B., Öst, Å., et al. (1984) · The Journal of Experimental Medicine · doi:10.1084/jem.159.2.537 · Cited by 44
Saif, M. W., Peccerillo, J., & Potter, V. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0831-6 · Cited by 44
Antibody Producing Human-Human Hybridomas
Olsson, L. (1984) · Springer eBooks · doi:10.1007/978-1-4684-4649-4_18 · Cited by 35
The future of monoclonal antibody technology
Zider, A. D., & Drakeman, D. L. (2010) · mAbs · doi:10.4161/mabs.12461 · Cited by 20
Natural Autoantibodies and Anti-Idiotypes
Gilles, J. G., Vanzieleghem, B., & Saint-Remy, J.-M. (2000) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2000-9817 · Cited by 19
Cited by
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Contribution of Organofluorine Compounds to Pharmaceuticals
Inoue, M., Sumii, Y., & Shibata, N. (2020) · ACS Omega · doi:10.1021/acsomega.0c00830 · Cited by 1,944
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Monoclonal Antibodies in Cancer Therapy
Zahavi, D., & Weiner, L. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 831
Metadata
- Authors
- Nelson, A. L., Dhimolea, E., & Reichert, J. M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-09-03
- Volume
- 9
- Issue
- 10
- Pages
- 767-774
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2065303540
- Cited by
- 1,026
- References
- 50
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.